Phase I/II Trial of Fenretinide/LXS Oral Powder (NSC 374551) Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Fenretinide; Ketoconazole
- Indications Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Aug 2020 Biomarkers information updated
- 28 Feb 2012 New trial record
- 28 Feb 2012 New trial record